Share

Save

Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity

PHASE1PHASE2RECRUITING

"Risk factors of Immune-ChEckpoint inhibitor MEdiated Liver, gastrointestinal, endocrine and skin Toxicity" (ICEMELT) study is a prospective multicenter cohort study, enrolling patients who are scheduled to receive (1) single agent PD1/L1 inhibitor; (2) PD1/L1 inhibitor plus CTLA4 inhibitor; (3) platinum-based chemotherapy + PD1/L1 inhibitor; (4) PD1/L1 inhibitor and tyrosine kinase inhibitor and (5) PD1/L1 inhibitor and vascular endothelial growth factor (VEGF) inhibitor.

info
Simpliy with AI

Study details:

This project is based on strong multidisciplinary collaboration between oncologists, gastroenterologists/hepatologists, immunologists and basic scientists affiliated with (1) Western Sydney University, (2) University of Sydney, (3) Western Sydney Local Health District (4) New South Wales Health Pathology, (5) Westmead Institute for Medical Research. Recruitment sites:. * Blacktown Mt Druitt Hospital.

* Westmead Hospital. Research samples collection, processing and storage:. * Blacktown Clinical School, Western Sydney University.

* Westmead Institute for Medical Research, the University of Sydney. * New South Wales Health Pathology. Potential patients will be identified by study investigators at Oncology clinics.

After informed consent, clinicopathological data including patients' demographics, past medical history, cancer staging, relevant anticancer treatment, response/progression and survival will be collected longitudinally. The following specimens will be collected from all participating patients at baseline (pre-treatment stage):. * Peripheral blood (3 x 10mL EDTA tubes).

* FibroScan (CAP score for elucidating pre-existing liver fibrosis). * Formalin-Fixed Paraffin-Embedded (FFPE) samples (one block) from core biopsies which is a part of routine care for cancer patients. The following specimens will be collected after IPI + NIVO therapeutic regimen will be commenced (week 6-9 after ICI-therapy commencement):.

• Peripheral blood (3 x 10mL EDTA tubes). Upon development of potential grade ≥2 irAEs, the following samples will be collected:. * Peripheral blood (3 x 10mL EDTA tubes).

* FibroScan (for patients with hepatic irAEs). * Tissue samples (if biopsies are collected as per standard of care for patients with immune-mediated colitis who will be required to undergo colonoscopy). Peripheral blood samples from patients will be collected using 10ml EDTA vacutainer tubes (x3) and processed within 12 hours of collection by research staff at each site.

Plasma will be used for miRNA assay. PBMCs will be split into 5 cryotubes and used for flow cytometry and single-cell sequencing. Consent to the study will allow researchers to access the baseline archive diagnostic FFPE tissue samples.

With implementing cutting-edge spatial analysis we aim to elucidate the impact of tumour-infiltrating immune microenvironment on clinical outcomes of ICI therapy. Fresh tissue samples obtained from patients with severe immune-mediated colitis will be processed to obtain total RNA and immune cells for sequencing and mass spectrometry (CyTOF). In addition, tissue samples will be analysed with in situ spatial profiling technologies to map multi-omic data on subcellular level and to determine its association with the clinical outcomes of cancer immunotherapy.

info
Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

  • Able to comprehend the requirements and procedures for the study and to provide informed consent before entering the study
  • Solid malignant tumour (stage III-IV)
  • Treated with ICI-based therapeutic regimens
  • Exclusion criteria

  • Inability to give written informed consent
  • Patients with a cognitive impairment, an intellectual disability or a mental condition that will interfere with the patient's ability to understand the requirements of the study
  • info
    Simplify with AI

    Eligibility

    Age eligible for study : 0 and older

    Healthy volunteers accepted : No

    Gender eligible for study: All

    Things to know

    Study dates

    Study start: 2020-12-15

    Primary completion: 2024-12-10

    Study completion finish: 2025-12-10

    study type

    Study type

    DIAGNOSTIC

    phase

    Phase

      PHASE1

      PHASE2

    trial

    Trial ID

    NCT04631731

    Intervention or treatment

    DIAGNOSTIC_TEST: Blood screening

    DIAGNOSTIC_TEST: Tissue screening

    Conditions

    • Gastric Cancer
    • Endometrial Cancer
    • Lung Cancer, Nonsmall Cell
    • Renal Cell Carcinoma
    • Melanoma
    • Hepatocellular Carcinoma
    • Mesothelioma
    Image related to Gastric Cancer
    • Condition: Gastric Cancer, Endometrial Cancer and more

    • DIAGNOSTIC_TEST: Blood screening and other drugs

    • Sydney, New South Wales, Australia and more

    • Sponsor: Western Sydney Local Health District

    Find a site

    Closest Location:

    Westmead Hospital

    Research sites nearby

    Select from list below to view details:

    • Westmead Hospital

      Sydney, New South Wales, Australia

    • Blacktown Mt Druitt Hospital

      Sydney, New South Wales, Australia

    Loading...

    Study Plan

    This section provides details of the study plan, including how the study is designed and what the study is measuring.

    How is the study designed?

    Participant Group/ArmIntervention/Treatment
    EXPERIMENTAL: Single agent PD-1/L1 inhibitor
    • Not Specified
    DIAGNOSTIC_TEST: Blood screening
    • Blood will be taken in order to elucidate transcriptomic and proteomic differences (1) pre- and post-ICI treatment commencement; (2) in patients with and without immune-related adverse events.
    EXPERIMENTAL: PD-1/L1 inhibitor + CTLA-4 inhibitor
    • Not Specified
    DIAGNOSTIC_TEST: Blood screening
    • Blood will be taken in order to elucidate transcriptomic and proteomic differences (1) pre- and post-ICI treatment commencement; (2) in patients with and without immune-related adverse events.
    EXPERIMENTAL: Platinum-based chemotherapy + PD-1/L1 inhibitor
    • Not Specified
    DIAGNOSTIC_TEST: Blood screening
    • Blood will be taken in order to elucidate transcriptomic and proteomic differences (1) pre- and post-ICI treatment commencement; (2) in patients with and without immune-related adverse events.
    EXPERIMENTAL: PD-1/L1 inhibitor + tyrosine kinase inhibitor
    • Not Specified
    DIAGNOSTIC_TEST: Blood screening
    • Blood will be taken in order to elucidate transcriptomic and proteomic differences (1) pre- and post-ICI treatment commencement; (2) in patients with and without immune-related adverse events.
    EXPERIMENTAL: PD-1/L1 inhibitor + VEGF inhibitor
    • Not Specified
    DIAGNOSTIC_TEST: Blood screening
    • Blood will be taken in order to elucidate transcriptomic and proteomic differences (1) pre- and post-ICI treatment commencement; (2) in patients with and without immune-related adverse events.

    What is the study measuring?

    Primary outcome

    Primary Outcome MeasurePrimary Outcome DescriptionPrimary Outcome Time Frame
    Differentially expressed genes in circulating immune cells between patients with and without irAEs.This objective will be achieved through single-cell sequencing.Week 0-48
    Expression of TIM-3, LAG3, VISTA and other inhibitory checkpoint molecules on tumour-infiltrating T cells.In order to ascertain this result, our objective is to utilize spatial transcriptomics and mass spectrometry.Week 0-48

    Secondary outcome

    Secondary Outcome MeasureSecondary Outcome DescriptionSecondary Outcome Time Frame
    Association of pre-treatment BMI, neutrophil-to-lymphocyte ratio and other clinical parameters with irAEs.Not SpecifiedWeek 0-48

    Frequently Asked Questions

    Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

    No questions submitted. Be the first to ask a question!

    You may be eligible to participate in this trial based on your search.Apply for study
    Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

    References

    Clinical Trials Gov: Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity

    Other trails to consider

    Top searched conditions